To date, expression of SF3B1 and its potential as a therapeutic target have not been explored in detail in PDAC nor in pancreatic cancer stem cells (CSCs), a small population of undifferentiated cells capable of initiating tumor generation, differentiation, and self-renewal, and thus, are key drivers of tumor evolution, metastasis, and relapse [18, 19]. Here, SF3B1 is linked to neoplasm.